Cardium Therapeutics (CRXM) Stock Price, News & Analysis

Company Overview

Cardium Therapeutics, Inc. was a biotechnology company focused on developing regenerative medicine and cardiovascular therapies. Its work centered on products intended to support tissue repair, wound healing and the treatment of ischemic heart disease.

The company’s principal commercial product was Excellagen, a topical collagen-based wound-management product designed to provide a matrix for tissue regeneration. Cardium also developed Generx, an investigational gene-therapy product intended to promote the growth of new blood vessels in patients with coronary artery disease and refractory angina. Generx remained a development-stage therapy and was not an approved treatment.

Cardium was headquartered in the United States and pursued opportunities in the regenerative-medicine and cardiovascular markets. Public information about its recent operations, leadership and geographic activities is limited, and the company’s publicly documented activities primarily relate to its historical product-development programs.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:CRXM
• Previous Symbol: NYSE:CXM
• CIK: 772320
• Web: www.cardiumthx.com
• Phone: (858) 414-1477
• Fax: 858-436-1001
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 14,490,000
• Free Float: N/A
• Market Cap: $1 thousand
• Optionable: Not Optionable
• Beta: N/A